Strides Arcolab receives Health Canada approval for Ondansetron 2 mg / ml injection

Strides Arcolab Ltd on August 08, 2007 has announced its first ANDS approval for Ondansetron Injection 2 mg / ml.

The product is licensed to an undisclosed partner in Canada and expects sales to commence in Q4 2007.

Ondansetron is a first amongst various sterile submissions the Company has submitted with Health Canada.

Arun Kumar - Vice Chairman and Managing Director of the Company stated "We are delighted with our first Canadian approval for an important sterile product and are delighted having achieved a further milestone in creating a global sterile injectable business".

The stock was trading at Rs.283.75, up by Rs.10 or 3.65%. The stock hit an intraday high of Rs.287.90 and low of Rs.277.70. The total traded quantity was 10375 compared to 2 week average of 12309.

Source : Equity Bulls

Keywords